Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin

Abstract

Angiotensin-1 converting enzyme I/D polymorphism is associated with the response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin. Subjects with DD genotype had a greater reduction in LDL-C, a higher rate of regression and a lower rate of progression of CAD.

An association study of 43 SNPs in 16 candidate genes with atorvastatin response

“…DNA preparation was as described previously. 18 TaqMan assays were obtained from ABI and used for all genotyping except for the CETP SNPs described previously. 16 The genetic effect of each polymorphism was evaluated using ANCOVA for each statin and for each clinical end point.…”

Genetic Markers

“…126 The Lipoprotein and Coronary Atherosclerosis Study demonstrated that subjects homozygous for the deletion (D) allele of the intron 6 insertion/deletion (I/D) polymorphism in the ACE gene exhibited a more favorable lipid response and angiographic regression of coronary atherosclerosis in response to treatment with fluvastatin. 127 In another study, homozygosity for the D allele of the ACE gene was associated with an improved antihypertensive response to ACE inhibitor therapy. 128 The I/D polymorphism also has been shown to influence blood pressure response to hydrochlorothiazide.…”

Clinical implications of pharmacogenomics of statin treatment

“…An insertion/ deletion variant within the ACE gene has been reported to predict risk of recurring coronary events following statin treatment in several studies. [94][95][96] The IGTB3 gene encodes the platelet-specific fibrinogen receptor and variation in this gene has been associated under basal conditions with elevated risk of coronary disease. 94,97 This increase in risk was reported to be abolished by statin treatment.…”